Amgen (AMGN +1%) shrugs off an early dip to trade higher even after Credit Suisse cut the shares to Neutral and lowered its price target to $90. The firm says the 3 key elements to its upgrade in July have been realized and there are few catalysts remaining in the near term.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs